WALTHAM, Mass., Oct. 19, 2021 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO) ("Thermo
Fisher") announced today that it intends to offer (the
"Offering") USD-denominated senior notes (the "Notes").
Thermo Fisher intends to use the
net proceeds of the Offering to pay a portion of the cash
consideration payable for the proposed acquisition of PPD,
Inc., a Delaware corporation (the
"PPD Acquisition"). Thermo Fisher
may also determine to use a portion of the net proceeds of the
Offering for general corporate purposes, which may include the
acquisition of companies or businesses, repayment and refinancing
of debt, working capital and capital expenditures or the repurchase
of its outstanding equity securities or it may temporarily invest
the net proceeds in short-term, liquid investments until they are
used for their ultimate purpose.
The joint book-running managers for the Offering are Barclays
Capital Inc., Morgan Stanley & Co. LLC, BofA Securities, Inc.,
Citigroup Global Markets Inc. and Mizuho Securities USA LLC.
The Offering is being made pursuant to an effective registration
statement on Form S-3 filed with the U.S. Securities and Exchange
Commission (the "SEC"). Prospective investors should read the
prospectus forming a part of that registration statement and the
prospectus supplement related to the Offering and the other
documents that Thermo Fisher has
filed with the SEC for more complete information about Thermo Fisher and the Offering. These documents
are available at no charge by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, Thermo
Fisher, the underwriters or any dealer participating in the
Offering will arrange to send you the prospectus if you request it
by calling Barclays Capital Inc. toll-free at 1-888-603-5847;
Morgan Stanley & Co. LLC toll-free at 1-866-718-1649; BofA
Securities, Inc. toll-free at 1-800-294-1322; Citigroup Global
Markets Inc. toll-free at 1-800-831-9146; or Mizuho Securities
USA LLC toll-free at
1-866-271-7403.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the Notes, nor shall there be any
offer, solicitation or sale of the Notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about Thermo Fisher's intended use of proceeds.
These statements involve a number of risks and uncertainties that
could cause actual results to differ materially from currently
anticipated results, including risks and uncertainties relating to
capital markets conditions, the pending acquisition of PPD, and
completion of the Offering. Additional important factors and
information regarding Thermo
Fisher's business that could cause actual results to differ
materially from those indicated by such forward-looking statements
are set forth in the prospectus and prospectus supplement dated
October 19, 2021 related to the
Offering, which is on file with the SEC and available in the
"Investors" section of our website under the heading "SEC Filings,"
and the documents incorporated by reference into the prospectus and
prospectus supplement. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so, even if circumstances change and,
therefore, you should not rely on these forward-looking statements
as representing our views as of any date subsequent to today.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue of approximately $35 billion. Our Mission is to enable our
customers to make the world healthier, cleaner and safer. Whether
our customers are accelerating life sciences research, solving
complex analytical challenges, improving patient diagnostics and
therapies or increasing productivity in their laboratories, we are
here to support them. Our global team of more than 90,000
colleagues delivers an unrivaled combination of innovative
technologies, purchasing convenience and pharmaceutical services
through our industry-leading brands, including Thermo Scientific,
Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab
Services and Patheon. For more information, please visit
www.thermofisher.com.
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/thermo-fisher-scientific-announces-offering-of-usd-denominated-senior-notes-301403162.html
SOURCE Thermo Fisher Scientific